SSB
IOVA icon

Sandy Spring Bank’s Iovance Biotherapeutics IOVA Stock Holding History

Sandy Spring Bank’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$2.66K Hold
800
– – ﹤0.01% 1015
2024
Q4 		$5.92K Hold
800
– – ﹤0.01% 954
2024
Q3 		$7.51K Hold
800
– – ﹤0.01% 907
2024
Q2 		$6.42K Hold
800
– – ﹤0.01% 953
2024
Q1 		$11.9K Buy
+800
New +$9.31K ﹤0.01% 827

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Sandy Spring Bank's IOVA Position: Q1 2025 in Review

Sandy Spring Bank held its Iovance Biotherapeutics (IOVA) position steady in Q1 2025 at 800 shares worth $2.66K. The position accounts for ﹤0.01% of the portfolio, ranked #1015.

Sandy Spring Bank first reported a position in IOVA in Q1 2024 and has held it in 5 quarters since. The position peaked at $11.9K in Q1 2024. 301 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

  • Sandy Spring Bank held 800 shares of Iovance Biotherapeutics worth $2.66K as of Q1 2025.
  • Sandy Spring Bank left its Iovance Biotherapeutics share count unchanged in Q1 2025.
  • Iovance Biotherapeutics made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #1015 holding.
  • Sandy Spring Bank first reported a position in Iovance Biotherapeutics in Q1 2024 and has held it in 5 quarters since.
  • Sandy Spring Bank's Iovance Biotherapeutics position peaked at $11.9K in Q1 2024.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.